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Abstract: Background: The 3-step avidin-biotin pretargeting approach is applied in patients with recurrent glioblastoma 
(GBM), using biotinylated anti-tenascin monoclonal antibody as the first step of pretargeting followed by avidin and 
90
Y-
biotin. 
Methods: The present study reviews objective response and overall survival rates in 502 glioblastoma patients treated with 
3-step radioimmunotherapy in our institute from December 1994 to December 2005. Patients underwent standard 
treatment before receiving Pretargeted Antibody-Guided Radionuclide Therapy with 
90
Y-biotin (PAGRIT
®
). 
Results: Of the 502 patients, 272 (54%) were evaluable for response and 375 (75%) for overall survival. 174 patients 
(64%) continued to progress after PAGRIT
®
, 77 (28%) obtained disease stabilization, and 21 (8%) showed objective 
tumor regression. Survival of the 375 evaluable patients was 98.4% at 6 months, 79.2% at 12 months, 51.7% at 18 months, 
and 30.7% at 24 months after the first cycle of PAGRIT
®
. All 375 received 3-step PAGRIT
®
 at recurrence of GBM. The 
median survival time from diagnosis was 19 months. 
Conclusion: The results from this retrospective analysis suggest that 
90
Y-biotin PAGRIT
®
 interferes with the progression 
of glioblastoma, prolonging survival in a larger number of patients. Our analysis forms the basis for further prospective 
trials, where radioimmunotherapy, which is known to be more effective in minimal residual disease, could be offered 
immediately after surgery. 
Keywords: Avidin-biotin, brain tumor, glioblastoma, monoclonal antibodies, pretargeting, radioimmunotherapy, tenascin. 
INTRODUCTION 
 Our experience at the European Institute of Oncology 
(Milan, Italy) of radioimmunotherapy (RIT) and the avidin-
biotin system for the treatment of high-grade gliomas 
(anaplastic astrocytoma and glioblastoma) began at the end 
of 1994, with the administration of RIT in a patient with 
recurrent anaplastic astrocytoma, who obtained a complete 
remission [1]. This patient is currently alive, 16 years after 
treatment. Thus, after this encouraging, albeit anecdotal 
result, the development of a 3-step RIT approach followed 
the conventional pathway of any new radiopharmaceutical. 
 In 1999 we published the 1
st
 Phase I-II study, evaluating 
the toxicity of the avidin-biotin pretargeting approach in 48 
patients with histologically confirmed high-grade glioma  
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(HGG) [2]. In this trial we showed that 3-step RIT with 
90
Y-
biotin produced limited toxicity up to the activity of 60 
mCi/m
2
 due to the favorable biodistribution of 
90
Y-DOTA-
biotin. Objective therapeutic responses evaluated according 
to WHO criteria were also documented in 25% of these 
patients. 
 The results obtained in the phase I-II study prompted us 
to apply the same approach in an adjuvant setting. Thirty-
seven patients with high-grade glioma (glioblastoma and 
anaplastic astrocytoma) and no evidence of disease after 
surgery and radiotherapy underwent, one month after 
completing the conventional treatment, treatment with Y-90-
biotin according to the previous phase I-II protocol. The 
median disease-free interval was 28 months and median 
survival 33.5 months for patients with glioblastoma. In the 
grade III glioma group, the median disease-free interval was 
56 months (range: 15-60) [3]. Unfortunately, this study was 
interrupted because budget restrictions prevented further 
purchase of clinical grade monoclonal antibodies avidin and 
90
Y-biotin, needed for the study. 
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 In another phase I-II study we investigated the safety 
profile and antitumor efficacy of locoregional RIT in 
recurrent high-grade glioma after second surgical debulking 
with implantation of an indwelling catheter in the surgical 
cavity. The maximum tolerated activity was 1110 GBq 
limited by neurologic toxicity. Again, an overall objective 
response was obtained in 25% of patients, with stable disease 
in 50% [4]. Following these results, we carried out a trial of 
locoregional radioimmunotherapy associated with oral 
chemotherapy (temozolomide) in order to achieve 
synergistic activity by combining radioactivity with 
chemotherapy. 75% of GBM patients obtained disease 
stabilisation, with a overall survival of 25 months and a 
progression free survival (PFS) of 10 months [5]. 
 More recently, in cooperation with the Neuro-Oncology 
Department of the National Neurological Institute "C. Besta" 
in Milan [6], we evaluated a combined therapeutic strategy: 
twenty-six patients with recurrent GBM were treated with 
local delivery of chemotherapy (mitoxantrone) and local pre-
targeted RIT through an indwelling catheter in the surgical 
cavity. PFS after second surgery for the entire group was, at 
6 and 12 months, 61% and 22%, respectively, while survival 
after recurrence was 80%, 53% and 42% at 6, 12 and 18 
months, respectively. The percentage of long-term survivors 
was very high: 42% of patients were still alive 18 months 
after the second surgery. 
 What these trials have in common is the fact that all the 
patients received RIT on the basis of a pretargeting strategy 
based on anti-tenascin monoclonal antibody and the avidin-
biotin system with 
90
Y as the radioactive source [1, 7]. In 
addition to these trials (all sponsored by Academic grants 
only), we treated numerous other recurrent glioblastoma 
patients, in progression after standard treatments, on a 
compassionate basis. 
 The aim of the present study was to retrospectively 
evaluate the efficacy of 3-step-PAGRIT
®
 in terms of overall 
survival in a large population of patients with recurrent 
glioblastoma. 
MATERIALS AND METHODS 
 The studies involved were approved by the Ethical 
Committee of the European Institute of Oncology and all 
patients, after being informed of the nature, aim and 
potential risks of the therapy, signed a consent form before 
starting therapy. Inclusion criteria were the same as 
described in our previous work [2]; in particular: the 
presence of recurrent/relapsed, tenascin-positive 
glioblastoma; baseline morphological evaluation with CT 
(Computed Tomography) scan or MRI (Magnetic Resonance 
Imaging); preserved bone marrow and kidney function; 
Karnofsky performance status (KPS) > 60%. Exclusion 
criteria were: KPS < 60; the presence of a known second 
cancer; history of allergic or anaphylactic reactions and 
pregnancy. 
Patients 
 Detailed patient characteristics are reported in Table 1. 
 As there is no Neurosurgery Unit at our Institute, the 
majority of patients were referred to us by colleagues from 
other cancer centers. A certain number patients, all in 
progression after standard treatments, arrived of their own 
volition after finding out about our institute via the Internet. 
Patients received RIT at disease progression, documented by 
a CT scan or MRI performed one month before therapy. 
Patients received RIT about 3-6 months after diagnosis: 
before RIT they were treated with surgery, conventional 
radiotherapy, and in few cases with chemotherapy. 
Table 1. Detailed Patients’ Characteristics 
 
Treated patients  502  
Males  316  
Females  186  
Age range (yrs)  18-82  
N° pts receiving CT  289  
KPS  > 60 
Pts evaluable for response  272/502 
Pts evaluable for survival  375/502 
 
 Routine blood and liver and renal function tests were 
performed before and after RIT. Antibodies against murine 
antibodies, avidin and streptavidin were assayed in serum 
30-40 days after RIT. Check-ups, including clinical 
examination (evaluation of performance status, quality of 
life, number of seizures, drug intake) and CT or MRI scans 
were scheduled at three-month intervals starting, when 
possible, two months after the end of RIT. 
 From December 1994 to December 2005 we treated 502 
glioblastoma patients with 3-step pre-targeted antibody 
guided radioimmunotherapy. All patients had previously 
received surgery (complete or only large biopsy) and 
radiotherapy; 289 had also received chemotherapy 
(platinum-based chemotherapy or, more recently, 
temozolomide) for histologically confirmed glioblastoma in 
progression at the time of RIT. 186 were females and 316 
were males (age range 18 - 82 years). 
 See Fig. (1) for the 3-step pretargeting approach. 
Radiolabelling and Administration Protocols 
 The radiolabelling procedure and pretargeting protocol 
were performed as previously described [2, 3]. 
 The biotinylated MoAbs were injected first, followed 24-
36 hours later by the administration of avidin and 
streptavidin. Patients remained under medical observation 
for an hour following administration to monitor possible 
reactions. 
 Ten minutes before the injection of radioactive biotin, 20 
mg of biotinylated human serum albumin was administered 
i.v. to reduce circulating levels of streptavidin (second 
chase). 
 To allow scintigraphic monitoring of radiolabel 
localisation, the therapeutic activity was mixed with 74-111 
MBq of the gamma source indium-111 bound to 0.05 mg of 
DOTA-biotin. The intravenous injected activity ranged from 
2.22 to 2.97 GBq/m2 (60-80 mCi/m2) and was administered 
24 hours after avidin and streptavidin infusion. 
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Data Analysis and Statistical Evaluation 
 The objective therapeutic response was evaluated with 
CT or MRI images of the brain before and after treatment. 
The first post-treatment evaluation was performed 60 days 
later and repeated every 2-3 months thereafter, when 
possible. 
 On the basis of these criteria and the WHO score, 
patients were classified as follows: 100% reduction: 
complete response (CR), >50% reduction: partial response 
(PR), <25% reduction: stable disease (SD), tumor 
enlargement > 25%: progressive disease (PD). 
 From March to July 2008, 502 enquiries were sent to the 
relevant Town Registries of Births, Deaths and Marriages 
asking for an update on patient status. A Kaplan-Meier 
estimation of survival and log-rank tests were applied. 
 Statistical analyses were performed with SPSS 10.0 for 
Windows computer software. 
RESULTS 
Toxicity and Quality of Life 
 Treatment was well-tolerated in all patients, without 
serious acute or late side-effects. A small number of patients 
who had previously received monoclonal antibodies and 
avidin for diagnostic purposes developed a mild allergic 
reaction (in particular, skin rash) during administration. No 
side-effects occurred from the biotinylated MoAb or 
90
Y 
biotin injections. 
 As previously described [2, 3], no renal or liver 
alterations were observed during follow-up. As regards 
hematological toxicity, the nadir of haematological values 
occurred 3 to 4 weeks after treatment and began with 
thrombocytopenia. Full recovery was observed in all patients 
after 4-6 weeks. No cases of fever, infection or bleeding, or 
other significant sequelae were reported. 
Immunological Response 
 The presence of antibodies against the injected reagents 
was assayed before and after treatment. Almost all patients 
(90%) developed anti-streptavidin antibodies, 70% 
developed anti-avidin antibodies, and 20% developed 
antibodies against the murine MoAbs. These results are very 
similar to data published previously by our group; in 
particular, they confirm the low frequency of reaction to 
murine MoAbs and the high immunogenicity of streptavidin
 
[8]. 
Therapeutic Effect 
 More than 75% of patients reduced or suspended steroids 
in the 2-4 months following treatment. 
 
Fig. (1). The pre-targeting approach (3-step). 
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 Therapeutic effects and data on survival are shown in 
Figs. (2, 3). 
 272 of the 502 treated patients were evaluable for 
therapeutic response on the basis of WHO criteria. We could 
assess only 272 out of 502 patients as the majority lived far 
away from our hospital and were lost to follow up. 
 When evaluating therapeutic response to RIT, we had to 
take into consideration a number of factors regarding our 
 
Fig. (2). Objective responses. 
 
Fig. (3). Survival data. 
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patients: heterogeneous population; different disease 
extension; different KPS at enrolment; and different tumor 
tenascin expression. Despite such diversity, interesting 
results were obtained: 21 patients (8%) showed a partial 
response (PR) at CT or MRI scans. 77 patients (28%) 
obtained disease stabilization and the remaining 174 patients 
(64%) had progressive disease at follow up. 
 In the PR group, 15 patients were in rapid progression 
after previous treatments (surgery and radiotherapy), while 
the remaining 6 patients showed slower disease progression. 
Duration of response was 13 months in the former PR group 
and 23 months in the latter. Median survival from diagnosis 
in this PR group was 26 months, with no side-effects from 
RIT and with good quality of life. 
Survival 
 502 enquiries were sent to the relevant Town Registries 
of Births, Deaths and Marriages asking for an update on 
patient status, with a response obtained for 375 (75%); in 
July 2008, the median survival time from diagnosis was 19 
months (95% CI 18 - 29). GBM cumulative survival was 
98.4% ± 0.9% at 6 months, 79.2% ± 2.1% at 12 months, 
51.7% ± 2.6% at 18 months, and 30.7% ± 2.4% at 24 months 
(Fig. 3). 
DISCUSSION 
 Glioblastoma remains a major challenge in oncology. A 
population-based study of newly-diagnosed GBM patients 
reported an overall survival of only 42.4% at 6 months, 
17.7% at 1 year and 3.3% at 2 years, despite surgery, 
radiotherapy and chemotherapy [9]. However, a more recent, 
randomized, multinational Phase III study showed that 
temozolomide improves outcome when administered in an 
integrative schedule during and following radiotherapy with 
respect to radiotherapy alone [10]. Salvage therapies after 
conventional treatments have proven to be ineffective, hence 
there is no accepted standard second-line care for recurrent 
glioblastoma patients. 
 Our 3-step pretargeting PAGRIT
®
 approach was offered 
to 502 glioblastoma patients from December 1994 to 
December 2005. All 502 patients, in disease progression 
after conventional treatments such as surgery, radiotherapy 
and chemotherapy, were referred to us from other hospitals; 
PAGRIT
® 
was proposed on a compassionate basis. Extension 
of surgery, kind of radiotherapy and/or chemotherapy 
received, and tumor molecular characteristics were not used 
as eligibility criteria (as in pilot phase I-II trials). We offered 
3-step PAGRIT
®
 to all glioblastoma patients with 
radiological evidence of disease progression, tenascin 
expression and KPS > 60. 
 Some interesting points emerge from our retrospective 
evaluation of this large population. 
 First, all patients tolerated the treatment very well, 
without acute or late side-effects. The low toxicity of high 
activities of 
90
Y-biotin using a 3-step pretargeting strategy 
shows an important advantage over the use of directly 
labeled antibodies [11] in that the radiolabelled material is 
cleared quickly from the blood-pool, has favorable 
biodistribution and is rapidly excreted via the kidneys. In this 
group of patients we confirmed, on a small sample of 
patients, dosimetric data that we reported in the study of 
1999 [2]: absorbed doses were 2.7±1.6 cGy /37 MBq in 
kidneys, 1.5±1.0 cGy/37 MBq in liver and 0.6± 0.3 cGy/ 37 
MBq in brain, while the dose delivered to the tumour was 
15.20±8.70 cGy/37 MBq. 
 Second, although we recruited a heterogeneous 
population for the 3-step RIT, which could be considered a 
limit of our study, we are nevertheless the only Nuclear 
Medicine Department to have administered this therapy with 
the pretargeting system in such a large group (502) of 
patients with recurrent glioblastoma. 
 Third, a therapeutic response was obtained in 21 (8%) 
patients and disease stabilization in 77 (28%). All 98 patients 
obtained an interruption of disease progression, which is 
significant where recurrent glioblastoma is concerned. 
However, these results are different from those previously 
described, where objective responses (complete and partial 
response) were observed in 29% of patients, with a further 
48% obtaining disease stabilization. We believe that this 
could be due to the different populations evaluated, 
especially if the KPS of enrolled patients, which was 
globally lower in the present retrospective study, is taken 
into consideration. This would be interesting to study in 
depth and could lead to the administration of RIT in an 
earlier phase of glioblastoma treatment, with patients in 
better clinical conditions. 
 Fourth, our most important finding concerned survival. 
Median overall survival from diagnosis was 19 months (in 
contrast to the 16 months observed in 31 patients reported in 
our first paper), with 30.7% of the patients still alive 2 years 
after RIT (Fig. 3). 
 Similar results were described by Stupp and coworkers in 
2009 [10] who published the long-term findings of the 
EORT-NCI phase III trial in glioblastoma patients 
randomised to receive external radiotherapy alone versus 
external radiotherapy plus temozolomide. Overall survival 
was 27.2% (95% CI 22.2-32.5) at 2 years. However, in 
Stupp’s study, treatment was administered at the beginning 
of the disease, whereas our patient population was in 
progression after surgery, radiotherapy and chemotherapy 
(the majority having received different, less active antiblastic 
drugs, e.g. platinum-based chemotherapy). 
 Other important results in terms of objective responses 
and overall survival in the treatment of glioblastoma, were 
obtained from other studies concerning bevacizumab, the 
best characterized antiangiogenic therapy, recently approved 
by FDA as a single agent for the treatment of patients with 
recurrent GBM following prior upfront, TMZ-based 
chemoradiotherapy [12,13]. Overall, treatment with 
bevacizumab in multiple GBM studies appears to be well 
tolerated with toxicity similar to that seen with other solid 
cancers treated with bevacizumab-containing therapies. 
Because of the extensive clinical experience with 
bevacizumab, practical issues regarding its administration, 
safety profile, and response to treatment have been described 
[14-16]. However, several important questions about the use 
of bevacizumab in GBM still remain unanswered, for 
example, the optimal therapeutic dosage, treatment schedule, 
treatment duration in responding patients and radiographic 
response criteria of bevacizumab are all unknown. 
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 Another important issue, that we have to consider, is that 
there is no consensus as to why the use of bevacizumab 
yields resistance to future treatments. Some investigators 
have found that patients with progression after bevacizumab 
developed perivascular fibrosis, which limited the amount of 
subsequent drug delivery to the tumor [17]. 
 However, as bevacizumab continues to be studied, it is 
evident that although there is an increase in PFS there is no 
change in overall survival (9 months in different studies) as 
compared with historical controls [18]; significative 
differences are also evident if we look at the results of our 
population, that can be considered similar for enrolment 
criteria. 
 The interesting results from our retrospective study, 
albeit not statistically comparable with those of other clinical 
trials, would seem to indicate that PAGRIT
® 
should be 
administered earlier in the glioblastoma treatment flowchart. 
In fact, when we administered RIT in an adjuvant setting 
after surgery, radiotherapy and chemotherapy [3], we 
obtained a median disease-free interval of 28 months with a 
median survival of 33.5 months. 
 3-step radioimmunotherapy is a multistep process 
designed to improve the efficiency of radiolabelled MoAb 
localization to tumor cells [19]. Typically, the MoAb is 
administered first and an appropriate time interval is allowed 
to permit the MoAb to localize and bind to its target, after 
which a radiolabelled, low-molecular-weight vehicle, is 
administered. The most frequently applied approach 
capitalizes on the extraordinarily high binding affinity of 
avidin for biotin. With this three-step process, glioma 
patients first receive biotinylated anti-tenascin MoAbs 
followed 24 hours later by avidin and then, approximately 18 
hours later, by the administration of an 
90
Y-labeled biotin 
conjugate. In our study, this approach was well tolerated by 
all patients, without any discomfort or acute or subacute 
side-effects. 
 Tenascin-C, a large, extracellular matrix glycoprotein, is 
widely expressed in the stroma and mesenchyme of tissues at 
various stages of differentiation. Increased tenascin-C 
expression occurs in a variety of pathologic states, including 
inflammation and wound healing, and in some tumors, such 
as breast, squamous cell, lung and prostate carcinomas, 
melanoma and malignant glioma [20-22]. Tenascin-C is 
expressed in more than 90% of gliomas and its expression 
increases with increasing tumor grade. Although its 
functions remain controversial, recent studies suggest that it 
plays a role in several cellular processes, including adhesion, 
migration and proliferation [23-28]. 
 In our study of a heterogeneous population of 
glioblastoma patients, we confirmed that 3-step 
radioimmunotherapy using the biotinylated anti-tenascin 
MoAb and the avidin-biotin system, is a safe therapy 
offering a clinical benefit in terms of improved survival. No 
enrolled patient experienced dose-limiting toxicity after the 
administration of 
90
Y—biotin. 
 These results could form the basis for further prospective 
trials, including those exploiting new radioisotopes, such as 
Lu-177 or alpha emitters, and provide a means to assess 
timing and scheduling of radioimmunotherapy in the 
therapeutic algorithm of high-grade glioma patients. They 
also open up numerous interesting possibilities for prospective 
evaluations, especially with regard to new treatment strategies. 
 Recently, our group developed a new tissue-pretargeted 
radionuclide treatment method called intraoperative 
avidination for radionuclide treatment (IART
®
). This 
approach is based on the intraoperative injection of avidin in 
surgical margins and tumor-surrounding tissues, followed, 
within 24 hours, by intravenous injection of radioactive 
biotin-DOTA. Clinical studies have shown that 
‘‘avidination’’ is a simple, well-tolerated and effective way 
of directing the localization of radioactive biotin. Tissue 
avidination, as in IART
®
, allows the creation of a transient 
artificial receptor for biotin and relies on the previously 
described tumor tropism of avidin [29-31]. This approach, 
already tested in breast cancer by our group, has been shown 
to be a safe procedure, delivering about 20 Gy to the tumor 
bed after a single i.v. injection of 3.7 GBq of 
90
Y-biotin [32-
34]. 
 The same principle can be applied in glioblastoma 
patients; neurosurgeons, immediately after removal 
(complete or partial) of the tumour, inject avidin into the 
tumour bed, and the next day the patient receives 
radiolabelled biotin i.v. as an anticipated boost to EBRT. 
 Patients normally receive external beam radiotherapy one 
month after surgery, thus giving glioblastoma cells sufficient 
time to spread into surrounding tissues. The use of IART
®
 in 
brain tumours can provide significant accelerating brain 
irradiation before starting the traditional treatment, thus 
offering a potential advantage in terms of time to progression 
and survival. It may, in fact, be advantageous to administer 
the radioisotopic treatment immediately after debulking 
surgery in order to exploit the greater permeability of the 
blood-brain barrier at that time. This would be expected to 
expose more malignant cells to the radionuclide and hence 
limit local and distant spread of the cancer. 
CONCLUSION 
 Glioblastoma multiforme, the most common primary 
tumor of the central nervous system, continues to have an 
unacceptable outcome. 
 Salvage therapies for malignant glioma patients with 
recurrent disease remain ineffective; such patients therefore 
represent a major challenge in neuroncology. 
 Radioimmunotherapy involving the administration of 
monoclonal antibodies and radioisotopes, in particular using 
the avidin-biotin system (PAGRIT
®
), represents an 
innovative therapeutic strategy to improve local tumor 
control and overall outcome when administered as part of a 
multimodality therapeutic regimen including traditional 
external-beam radiotherapy, systemic chemotherapy, and 
innovative treatments; this combined approach can be 
considered the most effective treatment currently available. 
Our hope is that the combination of surgery, radiotherapy, 
chemotherapy, new drugs and PAGRIT
® 
may provide a way 
of increasing life expectancy in glioblastoma patients. 
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